Use of MIB-1 (Ki-67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas

Dw, Hsu; Dn, Louis; Jt, Efird; Hedley‐Whyte, E. Tessa

doi:10.1097/00005072-199708000-00003

Cited by 89 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the studies have found significant differences in MIB-1 labeling indices between low and high grade astrocytomas [5,25,26]. In support to the previous studies, our results showed a significant direct correlation between MIB-1 LI and the histological grade.…”

Section: Discussionsupporting

confidence: 92%

“…A significant difference was detected between the diffuse and the anaplastic astrocytomas, and the anaplastic astrocytomas and GBMs. However, Hsu et al [25] and Rodriguez-Pereira et al [27] could not find a significant difference between the anaplastic astrocytomas and GBMs as regards MIB-1 LI.…”

Section: Discussionmentioning

confidence: 97%

“…This finding agreed with the results of McKeever et al [35], Korshunov et al [36] and Moskowitz et al [37] which could not establish any prognostic role for MIB-1 LI on Cox regression analysis in diffuse, anaplastic astrocytoma and GBMs respectively. On the other hand, Giannini et al [5] and Hsu et al [25] found that MIB-1 LI was an independent prognostic indicator in the diffuse and anaplastic astrocytomas. Also Wakimoto et al [33] confirmed the independent adverse effect of MIB-1 LI on survival in high-grade astrocytomas only.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors

et al. 2013

View full text Add to dashboard Cite

BackgroundThe histological grade is the gold standard for the evaluation of prognosis of astrocytic tumors. Nevertheless, morphologic criteria are not always accurate prognostic indicators.AimThe research investigates the expression of MIB-1 and DJ-1 in different grades of astrocytomas and evaluates the possible prognostic role of DJ-1 in these tumors in relation to other prognostic parameters including the MIB-1 labeling index.Materials and methodsImmunohistochemical expression of MIB-1 and DJ-1 was evaluated in 111 samples of astrocytic tumors comprising 28 diffuse astrocytomas, 38 anaplastic astrocytomas and 45 glioblastomas. The univariate survival analysis was done using the Kaplan-Meier method and the multivariate survival analysis was done using Cox proportional hazard model.ResultsThe statistical analysis revealed a significant correlation between each of DJ-1 and MIB-1 and the histological grade of astrocytomas. The univariate analysis showed that high grade, high DJ-1 score and MIB-1 labeling index ≥ 10.1 were associated with poor survival. Multivariate analysis for all the studied astrocytomas proved the independent prognostic significance of the histological grade and DJ-1 score. Meanwhile, the multivariate analysis for each grade emphasized that DJ-1 was the only independent prognostic indicator in high-grade astrocytomas.ConclusionThis study emphasized the effectiveness of high DJ-1 expression in predicting poor survival of astrocytoma patients, when compared to MIB-1. DJ-1 could be particularly important in cases with discrepancies between the morphologic criteria and clinical parameters.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1070116023943146

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry using the Ki67/MIB-1 monoclonal antibody is the most reliable and technically feasible method to measure cell proliferation or tumor growth fraction and has been extensively investigated in the gliomas. 3,[35][36][37][38][39][40][41][42][43] Several studies have documented a significant positive correlation between Ki67 labeling indices and tumor grade, and an inverse correlation with survival. In practice, Ki67 is often useful in limited biopsy samples in which the differential diagnosis involves diffuse astrocytoma versus anaplastic astrocytoma (Fig.…”

Section: Cell Proliferation In the Diffuse Gliomasmentioning

confidence: 99%

Glioma Diagnosis: Immunohistochemistry and Beyond

Dunbar

Yachnis

2010

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Clinicians and pathologists have been inundated by published reports of new and potentially interesting diagnostic, prognostic, and putative predictive "markers" whose expression (or loss) holds great promise for more enlightened diagnoses and ultimately better patient care. Although an understanding of therapeutically (and possibly diagnostically) relevant pathways of glioblastoma may be at hand, significant challenges remain. Many immunohistochemical and genetic tests have proven to be useful in the stratification of clinical trials, whereas the utility of many others for the day-to-day practice of pathology awaits further study and validation. The importance of critical literature review and careful consideration of practical issues such as test standardization, compliance, cost-effectiveness, and availability must all be considered before implementing any new diagnostic test. This review will focus on the role of immunohistochemistry in the routine diagnosis of astrocytic and oligodendrocytic tumors and in assisting with the diagnosis of some less common gliomas that have ependymal-like features. It will conclude with a summary of molecular and genetic studies, which not only hold great promise for improved diagnosis, but also reveal prognostic information on disease outcome and predict response to treatment or provide biologic targets for novel therapies.

show abstract

“…The most commonly used antibody is Ki67/MIB-1, which is an antibody directed against an antigen expressed during all active phases of the cell cycle [11]. However, due to a great spread of proliferation indices between different malignancy grades of astrocytic tumours, it is difficult to establish definitive thresholds values for prognostic and diagnostic purposes [9,12,13]. Nevertheless, most studies show that this marker is associated with both tumour grade and prognosis [9].…”

Section: Introductionmentioning

confidence: 99%

Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II

et al. 2013

View full text Add to dashboard Cite

BackgroundThe WHO classification system for astrocytomas is not considered optimal, mainly because of the subjective assessment of the histopathological features. Few prognostic variables have been found that stratify the risk of clinical progression in patients with grade II astrocytoma. For that reason there is a continuous search for biomarkers that can improve the histopathological diagnosis and prognostication of these tumours.AimThis study was designed to investigate the prognostic significance of the proliferative marker Mcm2 (minichromosome maintenance protein 2) in diffuse astrocytomas WHO grade II and correlate the findings with histopathology, mitoses, and Ki67/MIB-1 immunostaining.Method61 patients with histologically verified grade II astrocytoma (WHO 2007) were investigated. Paraffin sections were immunostained with anti-Mcm2, and the Mcm2 proliferative index (PI) was determined as the percentage of immunoreactive tumour cell nuclei.ResultsMcm2 PI was not associated with any histopathological features but correlated significantly with mitotic count and Ki67/MIB-1 PI (p<0.05). In the survival analyses Mcm2 showed trends to poorer survival, however, statistical significance was not achieved in the univariate analyses (p>0.05).ConclusionsIn our hands Mcm2 immunostaining has no advantage over Ki67/MIB-1 in the evaluation of grade II astrocytomas. Larger studies are needed to fully clarify the prognostic role of this biomarker.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1715002791944037

show abstract

Use of MIB-1 (Ki-67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas

Cited by 89 publications

References 0 publications

Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors

Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors

Glioma Diagnosis: Immunohistochemistry and Beyond

Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II

Contact Info

Product

Resources

About